

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

**VOLUNTARY ANNOUNCEMENT
INCLUSION OF THE COMPANY'S CORE PRODUCT
IN THE NATIONAL REIMBURSEMENT DRUG LIST**

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the **"Company"**) to inform the shareholders of the Company (the **"Shareholders"**) and potential investors of its recent business development.

The Board is pleased to announce that the Group's Core Product (i.e. Efsubaglutide Alfa), has been successfully included in the latest National Reimbursement Drug List (2025 Version) of China (the **"NRDL"**) for the indication of type 2 diabetes (**"T2D"**). The latest NRDL will officially take effect on 1 January 2026.

About Efsubaglutide Alfa

Efsubaglutide Alfa is the first domestic innovative humanised and long-acting GLP-1 receptor agonist developed by the Group and approved in January of this year in China for the treatment of T2D both as a monotherapy and in combination with metformin.

Efsubaglutide Alfa is designed for the treatment of T2D and other metabolic diseases. Efsubaglutide Alfa's clinical studies have demonstrated its fast action, strong and sustained efficacy, long half-life, and favourable safety profile.

- Efsubaglutide Alfa showed fast action, strong and sustained efficacy. With first four-week treatment, patients with T2D experienced a 1.1% reduction in hemoglobin A1c (HbA1c) levels with Efsubaglutide Alfa monotherapy (3.0 mg) in a Phase III clinical trial. Efsubaglutide Alfa also demonstrated outstanding glucose-lowering effects. In a randomised double-blind placebo control Phase III clinical trial, Efsubaglutide Alfa monotherapy with 1.0 mg and 3.0 mg dosing resulted in a statistically and clinically significant reduction in HbA1c of 1.7% and 2.2%, respectively, from their baselines at week 24.
- Efsubaglutide Alfa exhibited a long average half-life of 204 hours. The extended long-acting effect of Efsubaglutide Alfa enables low drug administration frequency in long-term disease management.
- Efsubaglutide Alfa has favourable safety profile. No cases of drug related level 2 or higher hypoglycemia were observed in Efsubaglutide Alfa's clinical trials.

Please refer to the prospectus of the Company dated 7 August 2025 for further details regarding the Group's Core Product (i.e. Efsubaglutide Alfa).

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the People's Republic of China, 7 December 2025

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.